CA2742842A1 - Releasable conjugates for nucleic acids delivery systems - Google Patents

Releasable conjugates for nucleic acids delivery systems Download PDF

Info

Publication number
CA2742842A1
CA2742842A1 CA2742842A CA2742842A CA2742842A1 CA 2742842 A1 CA2742842 A1 CA 2742842A1 CA 2742842 A CA2742842 A CA 2742842A CA 2742842 A CA2742842 A CA 2742842A CA 2742842 A1 CA2742842 A1 CA 2742842A1
Authority
CA
Canada
Prior art keywords
ch2ch2o
group
compound
ch2s
ch2ch2nh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2742842A
Other languages
English (en)
French (fr)
Inventor
Hong Zhao
Jing Xia
Prasanna Reddy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Belrose Pharma Inc
Original Assignee
Enzon Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Pharmaceuticals Inc filed Critical Enzon Pharmaceuticals Inc
Publication of CA2742842A1 publication Critical patent/CA2742842A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA2742842A 2008-11-17 2009-11-17 Releasable conjugates for nucleic acids delivery systems Abandoned CA2742842A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11532608P 2008-11-17 2008-11-17
US11535008P 2008-11-17 2008-11-17
US61/115,326 2008-11-17
US61/115,350 2008-11-17
PCT/US2009/064711 WO2010057154A1 (en) 2008-11-17 2009-11-17 Releasable conjugates for nucleic acids delivery systems

Publications (1)

Publication Number Publication Date
CA2742842A1 true CA2742842A1 (en) 2010-05-20

Family

ID=42170405

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2742842A Abandoned CA2742842A1 (en) 2008-11-17 2009-11-17 Releasable conjugates for nucleic acids delivery systems

Country Status (7)

Country Link
US (1) US20110230420A1 (enExample)
EP (1) EP2362729A1 (enExample)
JP (1) JP2012509066A (enExample)
CN (1) CN102231951A (enExample)
CA (1) CA2742842A1 (enExample)
TW (1) TW201029668A (enExample)
WO (1) WO2010057154A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9701715B2 (en) * 2012-10-05 2017-07-11 The University Of Kansas Conformationally-constrained kinked endosomal-disrupting peptides
US10766928B2 (en) 2012-10-05 2020-09-08 The University Of Kansas Targeted conformationally-constrained kinked endosomal disrupting peptides
US9365599B2 (en) 2012-10-26 2016-06-14 Korea Atomic Energy Research Institute N3S1 chelator-folate derivatives, preparation method thereof and composition for diagnosis or treatment of cancer containing the same as an active ingredient
US11458205B2 (en) 2015-08-04 2022-10-04 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
CA2987322C (en) * 2015-08-11 2020-02-11 Coherent Biopharma Multi-ligand drug conjugates and uses thereof
CN106466484B (zh) * 2015-08-11 2021-05-04 同宜医药（苏州）有限公司 一种具有细胞内吞介导功能的多靶向配体-药物偶联体
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
EP3512868A4 (en) 2016-09-14 2020-04-15 Duke University NANOPARTICLES BASED ON TRIBLOCK POLYPEPTIDE FOR THE DELIVERY OF HYDROPHILIC DRUGS
KR20190064600A (ko) 2016-09-23 2019-06-10 듀크 유니버시티 Lcst 거동을 갖는 비구조화된 비-반복적 폴리펩티드
US11648200B2 (en) 2017-01-12 2023-05-16 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
EP3658168A4 (en) 2017-06-30 2021-07-14 Duke University ORDER AND DISORDER AS A DESIGN PRINCIPLE FOR STIMULI-RESPONDING BIOPOLYMER NETWORKS
CN107629118A (zh) * 2017-10-31 2018-01-26 天津大学 基于组氨酸的靶向性穿膜肽载体及用途
WO2019147954A1 (en) 2018-01-26 2019-08-01 Duke University Albumin binding peptide-drug (aibiped) conjugates and methods of making and using same
WO2019213150A1 (en) 2018-04-30 2019-11-07 Duke University Stimuli-responsive peg-like polymer-based drug delivery platform
EP3829622A4 (en) 2018-08-02 2022-05-11 Duke University DOUBLE AGONIST FUSION PROTEINS
WO2020051541A1 (en) 2018-09-07 2020-03-12 Duke University Nanoparticulate drug delivery systems
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
US20250297258A1 (en) * 2021-07-07 2025-09-25 Ractigen Therapeutics Oligonucleotide-based delivery vehicle for oligonucleotides agents and methods of use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999042091A2 (en) * 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Use of polycations as endosomolytic agents
EP1389209B1 (en) * 2001-04-24 2009-04-08 Purdue Research Foundation Folate mimetics and folate-receptor binding conjugates thereof
ES2649817T3 (es) * 2002-04-05 2018-01-15 Roche Innovation Center Copenhagen A/S Compuestos oligom¿¿ricos para la modulaci¿®n de la expresi¿®n de HIF-1¿Á
US7713738B2 (en) * 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
WO2004106511A1 (ja) * 2003-05-30 2004-12-09 Nippon Shinyaku Co., Ltd. Ｂｃｌ−２の発現抑制をするオリゴ二本鎖ＲＮＡとそれを含有する医薬組成物
US20050261170A1 (en) * 2004-01-22 2005-11-24 Immunomedics, Inc. Folate conjugates and complexes
GB0415263D0 (en) * 2004-07-07 2004-08-11 Norwegian Radium Hospital Res Method
EP1812016A4 (en) * 2004-11-17 2010-07-14 Univ Maryland HIGH-BRANCHED HK-PEPTIDES AS EFFECTIVE CARRIER FROM SIRNA
EP1841867A1 (en) * 2005-01-24 2007-10-10 Avaris AB COMPLEX CONTAINING SiRNA, ShRNA OR ANTISENSE MOLECULE AND FUNCTIONAL ENTITY, FOR IMPROVED SPECIFICITY AND DELIVERY
CA2662520A1 (en) * 2006-09-15 2008-03-20 Enzon Pharmaceuticals, Inc. Polymeric conjugates containing positively-charged moieties
MX2009002855A (es) * 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Profarmacos polimericos dirigidos que contienen enlazadores multifuncionales.
EP3434259A1 (en) * 2007-05-04 2019-01-30 Marina Biotech, Inc. Amino acid lipids and uses thereof

Also Published As

Publication number Publication date
WO2010057154A1 (en) 2010-05-20
TW201029668A (en) 2010-08-16
EP2362729A1 (en) 2011-09-07
US20110230420A1 (en) 2011-09-22
CN102231951A (zh) 2011-11-02
JP2012509066A (ja) 2012-04-19

Similar Documents

Publication Publication Date Title
US20110230420A1 (en) Releasable conjugates for nucleic acids delivery systems
CA2723263A1 (en) Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
TW201021853A (en) Releasable cationic lipids for nucleic acids delivery systems
US20230277675A1 (en) Systemic delivery of oligonucleotides
US20090202573A1 (en) Polymeric conjugates containing positively-charged moieties
TW201023914A (en) Releasable polymeric lipids for nucleic acids delivery system
US20110111044A1 (en) Nanoparticle compositions for nucleic acids delivery system
CA2742689A1 (en) Branched cationic lipids for nucleic acids delivery system
CN109414408A (zh) 阳离子磺酰胺氨基脂质和两亲性两性离子氨基脂质
US20100279408A1 (en) Polymeric short interfering rna conjugates
MX2009002855A (es) Profarmacos polimericos dirigidos que contienen enlazadores multifuncionales.
TW201021852A (en) Releasable fusogenic lipids for nucleic acids delivery systems
AU2018295899B2 (en) Compounds and methods for trans-membrane delivery of molecules
US20220054645A1 (en) Targeted Delivery of Therapeutic Molecules
IL293589A (en) Peptide docking vehicle for targeted nucleic acid delivery and uses thereof
CN110650742A (zh) 使用经结构强化的S-TuD的新的癌症治疗方法
AU2023253037A1 (en) Conjugate and composition as well as preparation method therefor and use thereof
EP3617314A1 (en) Oligonucleotide derivative or salt thereof
CN114748640B (zh) 一种pH响应性的siRNA递送系统
CN121773124A (zh) 用于rna递送和疗法的基于脂质的增强剂
HK40017224B (en) Oligonucleotide derivative or salt thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20151117